| Methods |
4‐ to 6‐week placebo run‐in; inclusion criteria= mean sitting DBP 95‐115 mm Hg after run‐in, DBP could not differ by more than 7 mm Hg on 3 consecutive visits; 4‐week double‐blind treatment |
| Participants |
Enalapril 20 mg: n=50(33 males,17 females); mean age=59(10) years; baseline SBP=161.9(14.3) mm Hg, DBP=102.2(5.0) mm Hg, HR=76.2(8.4) bpm;
Placebo: n=49(27 males,22 females); mean age=56(9) years; baseline SBP=158.3(14.1) mm Hg, DBP=101.7(4.5) mm Hg, HR=71.8(7.8) bpm |
| Interventions |
Enalapril 20 mg once daily;
Placebo;
administered in the morning |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
Mean change from baseline in trough sitting HR;
WDAE |
| Notes |
BP change and SD of change reported; endpoint BP and SD not reported; SBP/DBP data from Table 2, p. 788; Jadad score=3; funding source= Hoffman‐La Roche |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
